Ifp Advisors, Inc Allakos Inc. Transaction History

Ifp Advisors, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 06, 2022	BUY	$2.6 - $6.14 $754 - $1,780	290 New	290 $9,000
Q2 2022 Aug 12, 2022	SELL	$2.6 - $6.14 $754 - $1,780	-290 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$5.08 - $9.81 $1,473 - $2,844	290 New	290 $1,000
Q3 2021 Oct 06, 2021	SELL	$76.53 - $110.43 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	SELL	$85.37 - $114.1 $256 - $342	-3 Closed	0 $0
Q1 2021 Apr 30, 2021	SELL	$109.73 - $153.66 $219 - $307	-2 Reduced 40.0%	3 $0
Q4 2020 Jan 25, 2021	BUY	$79.58 - $152.45 $159 - $304	2 Added 66.67%	5 $0
Q3 2020 Oct 29, 2020	BUY	$66.43 - $90.99 $199 - $272	3 New	3 $0

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.